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Mitochondrial dysfunction during acute metabolic crises is con-
sidered an important pathomechanism in inherited disorders of
propionate metabolism, i.e. propionic and methylmalonic acid-
urias. Biochemically, these disorders are characterized by ac-
cumulation of propionyl-CoA and metabolites of alternative
propionate oxidation. In the present study, we demonstrate un-
competitive inhibition of PDHc (pyruvate dehydrogenase com-
plex) by propionyl-CoA in purified porcine enzyme and in sub-
mitochondrial particles from bovine heart being in the same
range as the inhibition induced by acetyl-CoA, the physiological
product and known inhibitor of PDHc. Evaluation of similar
monocarboxylic CoA esters showed a chain-length specificity for
PDHc inhibition. In contrast with CoA esters, non-esterified fatty
acids did not inhibit PDHc activity. In addition to PDHc inhibition,
analysis of respiratory chain and tricarboxylic acid cycle enzymes
also revealed an inhibition by propionyl-CoA on respiratory chain
complex III and α-ketoglutarate dehydrogenase complex. To
test whether impairment of mitochondrial energy metabolism is
involved in the pathogenesis of propionic aciduria, we performed
a thorough bioenergetic analysis in muscle biopsy specimens of
two patients. In line with the in vitro results, oxidative phos-
phorylation was severely compromised in both patients. Further-
more, expression of respiratory chain complexes I–IV and the
amount of mitochondrial DNA were strongly decreased, and
ultrastructural mitochondrial abnormalities were found, high-
lighting severe mitochondrial dysfunction. In conclusion, our
results favour the hypothesis that toxic metabolites, in parti-
cular propionyl-CoA, are involved in the pathogenesis of in-
herited disorders of propionate metabolism, sharing mechanistic
similarities with propionate toxicity in micro-organisms.
Key words: mitochondrial dysfunction, mitochondrial toxin,
oxidative phosphorylation, propionic aciduria, propionyl-CoA,
pyruvate dehydrogenase complex.
INTRODUCTION
Propionyl-CoA is an intermediate metabolite in the final com-
mon catabolic pathways of the amino acids L-isoleucine, L-
methionine, L-threonine and L-valine as well as odd-chain fatty
acids and cholesterol. It is carboxylated by propionyl-CoA car-
boxylase (EC 6.4.1.3) to methylmalonyl-CoA and then is con-
verted by methylmalonyl-CoA mutase (EC 5.4.99.2) into suc-
cinyl-CoA, subsequently being fed as anaplerotic precursor into
the tricarboxylic acid cycle. Inherited deficiency of propionyl-
CoA carboxylase, i.e. PA (propionic aciduria), is biochemically
characterized by an accumulation of propionate, 3-hydroxy-
propionate, 2-methylcitrate and propionylglycine, demonstrating
alternative propionate oxidation in these patients. Furthermore,
metabolic acidosis, ketosis, increased lactate concentrations,
hypoglycaemia and hyperammonaemia are found during meta-
bolic derangement, highlighting secondarily compromised energy
metabolism and ammonia detoxification [1]. Clinically, PA is
complicated by acute life-threatening metabolic crises, which are
precipitated by catabolic state and result in multiple organ failure
or even death if untreated [1]. Like other organic acidurias (e.g.
methylmalonic aciduria), age at clinical onset and disease course
may vary between individual patients presenting with neonatal
metabolic encephalopathy (neonatal onset), recurrent episodes of
ketoacidotic coma or Reye-like syndromes (chronic intermittent
form), or psychomotor retardation and failure to thrive in the ab-
sence of acute crises (chronic progressive form). Similarly to
neonatal onset of PA patients, PCCA−/− mice, a transgenic mouse
model for PA, develop lethal ketoacidosis shortly after birth [2].
Despite improvements in the diagnostic work-up and manage-
ment of affected patients during the last decades, the neurological
outcome remains disappointing in PA patients [1,3]. In particular,
mental retardation and movement disorders secondary to cortical
atrophy, leucoencephalopathy and basal ganglia injury are still
frequently found even in early diagnosed children. The biochem-
ical abnormalities found during acute metabolic crises have led to
the suggestion that impairment of OXPHOS (oxidative phospho-
rylation) is crucial for the pathogenesis of this disease. Notably,
accumulating metabolites of alternative propionate oxidation
have been suggested to act as endogenous inhibitors of energy
metabolism in different in vitro models [4–7]; however, the patho-
physiological impact of these findings on PA still remains unclear.
Here, we report severe disturbance of mitochondrial energy
metabolism in muscle tissues from two PA patients and demon-
strate in vitro that propionyl-CoA-induced mitochondrial dys-
function plays a central role in this scenario.
Abbreviations used: BN-PAGE, blue native PAGE; E1, pyruvate decarboxylase; E3, dihydrolipoyl dehydrogenase; KGDHc, α-ketoglutarate dehydro-
genase complex; mtDNA, mitochondrial DNA; ND6, NADH dehydrogenase 6; OXPHOS, oxidative phosphorylation; PA, propionic aciduria; PDHc, pyruvate
dehydrogenase complex; SMP, submitochondrial particle.
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EXPERIMENTAL
Patient 1
This girl was born at term as the second child of non-consangui-
neous Caucasian parents. At the third day of life, she was admitted
because of progressive feeding refusal, lethargy and abnormal
breathing. Laboratory investigations revealed a severe metabolic
acidosis [pH 7.01; pCO2 18 mmHg (1 mmHg = 0.133 kPa); bi-
carbonate 5 mM; base excess 25 mM] and hyperammonaemia
(830 µM; normal <80 µM). The amino acid analyses in plasma
revealed no abnormalities. Analysis of urine organic acids by
GC/MS showed biochemical abnormalities characteristic for
PA with increased concentrations of β-hydroxybutyric acid
(6373 mmol/mol of creatinine; control range: 0–45 mmol/mol
of creatinine), β-hydroxypropionic acid (21461 mmol/mol of
creatinine; control range: 0–160 mmol/mol of creatinine), β-hy-
droxyisovaleric acid (176 mmol/mol of creatinine; control range:
0–10 mmol/mol of creatinine), lactic acid (776 mmol/mol of cre-
atinine; control range: 0–270 mmol/mol of creatinine), propionyl-
glycine, methylcitrate and tiglylglycine. The last three metabolites
were not quantified. The concentration of free carnitine in plasma
was decreased (10 µM; control range 20–200 µM), and the
concentration of total carnitine was below normal. A carnitine
profiling was not done at the time of admission, but later on it
repeatedly showed increased concentrations of propionylcarnitine
varying between 40 and 80 µM (normal <4 µM).
Extracorporal detoxification was performed. Besides a high
caloric intake and transient stop of protein intake, metronidazol,
lactulose, L-carnitine and biotin were added in the acute treat-
ment phase. At age 10 days, she was dismissed from the neonatal
intensive care unit and then was nursed in the metabolic ward.
The only abnormal clinical sign at that time was a slight
axial hypotonia. Maintenance treatment consisted of a natural
protein intake (1.0 g/kg per day) supplemented with an amino
acid mixture lacking precursor amino acids of propionyl-CoA
(i.e. L-isoleucine, L-methionine, L-threonine and L-valine) and
application of L-carnitine and biotin. Analysis of propionyl-
CoA carboxylase activity in leucocytes showed deficient ac-
tivity of this enzyme (0.1 nmol · h−1 · mg of protein−1; control:
2.3 nmol · h−1 · mg of protein−1) and thus confirmed the diagnosis
of PA. She was admitted to hospital numerous times due to meta-
bolic derangements, the last one, at age 5 years, being fatal. The
child had a severe myopathic appearance during life, which was,
in combination with repeatedly increased blood lactate concen-
trations (2.0–7.2 mM; normal <2.1 mM), a reason to perform a
muscle biopsy for mitochondrial studies.
Patient 2
This boy was born at term following an uncomplicated preg-
nancy and delivery. At the third day of life, tachypnoea and
metabolic acidosis led to a detailed metabolic investigation. The
investigation of amino acids in plasma revealed an increased
concentration of glycine (722 µM; 80–440 µM). As for patient 1,
urine organic acid analysis showed an increased concentration
of β-hydroxybutyric acid (17818 mmol/mol of creatinine), β-
hydroxypropionic acid (25096 mmol/mol of creatinine), β-hy-
droxyisovaleric acid (34 mmol/mol of creatinine), lactic acid
(1322 mmol/mol of creatinine), propionylglycine, methylcitrate
and tiglylglycine. Propionyl-CoA carboxylase activity in cultured
skin fibroblasts was strongly decreased (0.3 nmol · h−1 · mg of
protein−1), confirming the diagnosis of PA that was treated ac-
cording to standard methods (see also the Patient 1 subsection).
The child always had a myopathic appearance and exercise
intolerance. Standard exercise testing at age 5 years showed an
Table 1 Bioenergetic analysis in muscle tissue of PA patients
Radiochemical analysis of coupled mitochondria (A) using [1-14C]pyruvate, [U-14C]malate
and [1,4-14C]succinate. Spectrophotometric analyses of single enzymes of the respiratory
chain, tricarboxylic acid cycle, PDHc (B), ATP and phosphocreatine production rate (C), and
citrate synthase (D). Analyses were performed in muscle biopsy specimens of both patients.
Activities are expressed as nmol · h−1 · mg of protein−1 (A), m-unit/unit of citrate synthase (B),
nmol · h−1 · m-unit−1 citrate synthase (C) and m-unit/mg of protein (D). The production of ATP
and phosphocreatine was determined to establish the total mitochondrial energy-generating
capacity of the muscle mitochondria of both patients. n.m., not measured.
Experiment Patient 1 Patient 2 Control range
A. Oxidation of pyruvate, malate and succinate
[1-14C]Pyruvate + malate 0.13 0.56 3.61–7.48
[1-14C]Pyruvate + carnitine 0.21 0.59 2.84–8.24
[U-14C]Malate + pyruvate + malonate 0.18 0.32 4.68–9.62
[U-14C]Malate + acetylcarnitine + malonate 0.46 1.32 3.43–7.30
[U-14C]Malate + acetylcarnitine + arsenite 0.43 1.45 2.05–6.39
[1,4-14C]Succinate + acetylcarnitine 0.27 0.82 2.54–6.39
B. Single enzyme activity
Complex I 16 34 70–250
Complex II 59 38 67–177
Complex III 446 989 2200–6610
Complex IV 507 593 810–3120
Complex II + coenzyme Q + complex III 87 118 300–970
PDHc 6 10 34–122
PDHc-E1 1.08 1.52 1.23–4.13
PDHc-E3 353 533 760–2630
KGDHc n.m. 3 23–49
C. ATP and phosphocreatine
ATP + phosphocreatine 10 0.0 42–81
D. Mitochondrial reference enzyme
Citrate synthase 81 147 37–162
increase in blood lactate from normal concentrations at rest to
20 mM lactate after a short run of approx. 50 m. This was the
reason for further bioenergetic analyses in muscle tissue (Table 1).
Muscle and skin biopsies
Muscle biopsies (musculus vastus lateralis dexter) and forearm
skin punch biopsies were performed in both patients. Furthermore,
fibroblast cultures from patients with confirmed diagnosis of
PDHc (pyruvate dehydrogenase complex) deficiency (n = 3) and
healthy volunteers (n = 12) were used. Biopsies and subsequent
experiments were performed after receipt of informed consent.
The study was approved by the Institutional Review Board
(Medical Faculty of Heidelberg, Heidelberg, Germany). Further
investigations were performed in muscle tissue (musculus quad-
riceps femoris) of wild-type C57Bl/6 mice. Animal care followed
the official governmental guidelines and was approved by the
government ethics committee.
Human skin fibroblast cultures
Human skin fibroblasts from forearm skin biopsies were cultivated
under standard conditions in Dulbecco’s modified Eagle’s me-
dium at 37 ◦C supplemented with 10% (v/v) fetal calf serum,
100 µg/ml penicillin, 100 µg/ml streptomycin, 2.5 µg/ml of
fungizone and 200 µM uridine until confluency [8]. Medium
was changed twice a week. Each cell culture was tested for con-
tamination with Mycoplasma spp. before enzyme analysis.
Preparation of tissue extracts
Fibroblast and muscle homogenates as well as SMPs (sub-
mitochondrial particles) from bovine heart were prepared as
previously described [8–10].
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PDHc activity
Spectrophotometric analysis of PDHc activity [E1 (pyruvate
decarboxylase), EC 4.1.1.1; E2 (dihydrolipoyl transacetylase),
EC 2.3.1.12; E3 (dihydrolipoyl dehydrogenase), EC 1.8.1.4]
was performed in purified porcine PDHc (Sigma–Aldrich,
Schnelldorf, Germany), in SMP, and in homogenates from
human skin fibroblasts and quadriceps muscle biopsy specimens
using a p-Iodonitrotetrazolium Violet-coupled system as pre-
viously described [8]. In brief, steady-state activities of PDHc
were recorded using a computer tuneable spectrophotometer
(SPECTRAmax Plus 384 microplate reader; Molecular Devices,
Sunnyvale, CA, U.S.A.) operating in the dual wavelength mode.
Samples were analysed in temperature-controlled 96-well plates
in a final volume of 300 µl. PDHc (purified enzyme, 160 m-
units/ml; SMP, 1.2 mg of protein/ml; fibroblast homogenate,
4 mg of protein/ml) was assayed in a buffer containing 0.05 M
potassium phosphate, 2.5 mM NAD+, 5 mM L-carnitine, 0.2 mM
thiamine pyrophosphate, 0.1 mM CoA, 0.1% (v/v) Triton
X-100, 1 mM MgCl2, 1 mg/ml BSA, 0.6 mM p-Iodonitrotetra-
zolium Violet and 6.5 µM phenazine methosulphate, which was
adjusted to pH 7.5 at 25 ◦C. PDHc activity was determined
as p-Iodonitrotetrazolium Violet reduction at a wavelength of
λ= 500–750 nm. The specificity of this assay was confirmed by
complete inhibition of PDHc activity by the specific E1 inhibitor
3-fluoropyruvate (5 mM).
To investigate the effect of acetyl-CoA and propionyl-CoA,
we varied the concentrations of these CoA esters (0–1 mM) and
pyruvate (0–0.1 mM). Additional experiments were performed
using short-chain (acetyl-CoA [C2], propionyl-CoA [C3] and
butyryl-CoA [C4]), medium-chain (hexanoyl-CoA [C6], octanoyl-
CoA [C8] and decanoyl-CoA [C10]) and long-chain (myr-
istoyl-CoA [C14] and palmitoyl-CoA[C16]) acyl-CoA esters as
well as corresponding short- and medium-chain fatty acids (up
to 1 mM; all adjusted to pH 7.5).
Spectrophotometric analysis of KGDHc (α-ketoglutarate
dehydrogenase complex) activity
Spectrophotometric analyses of KGDHc [KGDHc subunits: E1k
(α-ketoglutarate dehydrogenase), EC 1.2.4.2; E2k (dihydrolipoyl
succinyltransferase), EC 2.3.1.61; and E3] were performed in
SMP and muscle homogenates as previously described [10].
In brief, KGDHc (650 m-units/ml) was assayed in a buffer con-
taining 35 mM potassium phosphate, 5 mM MgCl2, 0.5 mM
EDTA, 0.5 mM NAD+, 0.2 mM thiamine pyrophosphate,
0.04 mM CoA-SH (where SH is thiol group) and 2 mM α-
ketoglutarate, which was adjusted to pH 7.4 at 30 ◦C. KGDHc
activity was determined as NAD+ reduction at a wavelength
of λ= 340–400 nm. The effect of propionyl-CoA on KGDHc
activity was tested in analogy to PDHc (n = 8).
Spectrophotometric analysis of OXPHOS complexes I–V
The catalytic activities of respiratory chain complexes I–V in
SMP and muscle homogenates were investigated as previously
described [9–14]. The addition of standard respiratory chain in-
hibitors [complex I, 2-n-decylquinazolin-4-yl-amine (1 µM);
complex II, thenoyltrifluoroacetone (8 mM); complex III, anti-
mycin A (1 µM); complex IV, NaCN (2 mM); complex V,
oligomycin (80 µM)] revealed good inhibitory responses (93–
100% of control activity, P < 0.001 versus controls), confirming
a high specific enzyme activity in our assay system. Acyl-CoA
esters (C2, C3, C4 and C6) and corresponding fatty acids (all
adjusted to pH 7.4) were added and effects on single respiratory
chain complexes I–V were determined at concentrations up
to 1 mM each (complex I, 0.5 mg/ml of protein; complex II,
0.3 mg/ml of protein; complex III, 0.1 mg/ml of protein, com-
plex IV, 0.01 mg/ml of protein; complex V, 1.1 mg/ml of protein).
By analogy, complex III activity was also investigated in isolated
complex III from bovine heart (0.1 mg/ml of protein).
Radiometric analysis of mitochondrial OXPHOS
Radiometric analysis was performed in freshly prepared quad-
riceps-muscle biopsy specimens from PA patients. Supernatants
(600 g) were prepared and oxidation rates of [1-14C]pyruvate, [U-
14C]malate and [1,4-14C]succinate were determined as previously
described [14–16].
ATP production
Spectrophotometric analysis of ATP production was determined
in muscle biopsies of PA patients using unlabelled pyruvate, mal-
ate and succinate as described previously [14]. In brief, spectro-
photometric analysis of ATP production is coupled with the
formation of NADPH (λ= 320–400 nm, 25 ◦C). The test principle
consists of two enzyme reactions. In the first step, glucose
(30.3 mM) and ATP are catalysed to glucose 6-phosphate and
ADP by hexokinase (EC 2.7.1.1). Subsequently, glucose-6-phos-
phate dehydrogenase (EC 1.1.1.49) catalyses glucose 6-phosphate
and NADP+ to 6-phosphogluconolacton and NADPH.
Protein electrophoresis of muscle tissue
One- and two-dimensional BN-PAGE (blue native PAGE) and
subsequent in-gel activity assays and Western-blot analysis
were performed in muscle biopsies of PA patients as described
previously [17]. Antibodies against OXPHOS complex I [subunits
39 kDa and ND6 (NADH dehydrogenase 6)], complex II (sub-
unit 70 kDa) and complex III (subunit Core 2) were obtained from
Molecular Probes (Eugene, OR, U.S.A.), and against cyclophilin
B, from Affinity Bioreagents (Golden, CO, U.S.A.).
Electron microscopy of muscle tissue
Electron microscopical examination of muscle biopsies of PA
patients was done according to standard methods.
Data analysis
Enzyme activities were normalized to citrate synthase (EC
2.3.3.1) activity and the protein concentration of the same sample
[18,19]. Results were expressed as means +− S.D. for at least
three independent experiments. ANOVA followed by post hoc
Bonferroni’s multiple comparison test (for three or more groups)
or Student’s t test (for two groups) were used to calculate
statistical differences between groups. Results are presented as
the means +− S.D. if not indicated differently. Statistics were
calculated using SPSS for Windows 12.0 software. P < 0.05 was
considered significant.
RESULTS
Propionyl-CoA inhibits PDHc
In purified porcine PDHc, propionyl-CoA showed an inhibition
of PDHc activity, being uncompetitive with respect to pyruvate
(Figure 1). Notably, this inhibitory effect was in the same range
as for acetyl-CoA, the physiological product and known inhibitor
of PDHc (Figure 2). For propionyl-CoA (0.125–1 mM), the
inhibition constant (K i) ranged from 101 to 422 µM [3–12 times
Km (Michaelis–Menten constant)] and for acetyl-CoA (0.125–
1 mM), it ranged from 90 to 256 µM (2–7 times Km). The Km was
35 +− 0.5 µM for pyruvate. Similar results were found in SMP
from bovine heart (results not shown).
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Figure 1 Inhibition of PDHc by propionyl-CoA
Spectrophotometric analysis in purified PDHc from porcine heart demonstrates uncompetitive
inhibition of PDHc activity by propionyl-CoA with respect to pyruvate (Pyr) as demonstrated by
a Lineweaver–Burk plot. Values are given as the means +− S.D. (where no error bars are visible
the S.D. is within the symbol). Experiments were performed at least in triplicate.
Figure 2 Inhibition of PDHc by acetyl-CoA
Spectrophotometric analysis in purified PDHc from porcine heart demonstrates uncompetitive
inhibition of PDHc activity by acetyl-CoA with respect to pyruvate (Pyr) as demonstrated by a
Lineweaver–Burk plot. Values are given as the means +− S.D. (where no error bars are visible
the S.D. is within the symbol). Experiments were performed at least in triplicate.
Next, we determined PDHc activity in fibroblast homogenates
from two PA patients. Assay conditions allowed enzyme analysis
in the absence of intracellularly formed propionyl-CoA. Notably,
fibroblasts from both patients revealed PDHc activities within
the control range, confirming our hypothesis of secondary PDHc
inhibition induced by propionyl-CoA (Figure 3). As expected,
patients with confirmed PDHc deficiency showed a reduced PDHc
activity in fibroblasts (Figure 3).
Acyl-CoA esters inhibit PDHc in a chain-length-specific manner
To investigate whether PDHc inhibition was dependent on the
chain length of acyl-CoA esters, we investigated the inhibitory
effect of similar monocarboxylic CoA esters ranging from C4 to
C16 in purified porcine PDHc. In fact, PDHc was also effectively
inhibited by C4, C10, C14 and C16 but less effectively by C6 and
C8 esters (Figure 4A). In contrast, short-chain fatty acids (up to
1 mM) did not inhibit of PDHc (Figure 4B). These results were
confirmed in SMP from bovine heart (results not shown).
Figure 3 Spectrophotometric analysis of PDHc activity in human skin
fibroblasts
Spectrophotometric analysis of PDHc activity was performed in human skin fibroblasts from
healthy volunteers (n = 12), patients with PA (n = 2) and primary PDHc deficiency (n = 3). The
horizontal bar represents the mean for the control group and the dotted lines indicate the range
of the control group.
Alternative effects of propionyl-CoA on energy metabolism
Bioenergetic investigations in muscle tissue of both PA patients
showed strongly reduced oxidation of pyruvate and PDHc activity
as well as a diminished ATP plus phosphocreatine production
(Table 1). In addition, decreased oxidation of succinate and malate
as well as of almost all measured enzymes and enzyme complexes
of mitochondrial respiratory chain and tricarboxylic acid cycle
were found in these patients (Table 1).
Consistent with the enzymatic measurements is the decrease in
the OXPHOS complexes I–IV in patient 2 observed with one- and
two-dimensional BN-PAGE in combination with Western blotting
and a complex I in-gel activity assay (Figure 5).
The general decrease in the amount of these OXPHOS com-
plexes suggests a destabilization and increased breakdown of
mitochondria. The observed reduction in mtDNA (mitochondrial
DNA) content of about approx. 50% in patients 1 and 2 is in line
with this suggestion. By analogy to these biochemical results,
histopathology of muscle biopsies showed numerous signs of
mitochondrial alteration indicating disturbance of mitochondrial
energy metabolism, such as inclusion of many lipid droplets in
muscle fibres of patient 1 (Figure 6A), crystalline inclusions
(Figure 6B) and large swollen mitochondria with dark globular
inclusions (Figure 6C).
Since bioenergetic analyses in both PA patients suggested
additional mechanisms acting in concert with propionyl-CoA-
induced PDHc inhibition, we investigated whether propionyl-
CoA and other short-chain acyl-CoA esters revealed inhibitory
effects on respiratory chain and tricarboxylic acid cycle enzymes.
We found no effect of short-chain acyl-CoA esters and fatty acids
on respiratory complexes I, II, IV and V in SMP (results not
shown). However, by analogy to muscle tissue of PA patients,
propionyl-CoA (1 mM) induced a mild inhibition of com-
plex III activity in SMP (72 +− 5% of controls) and in isolated
complex III from bovine heart (81 +− 8% of controls). In addition,
the activity of KGDHc, a rate-limiting tricarboxylic acid cycle
enzyme complex, was also decreased by propionyl-CoA (1 mM
propionyl-CoA: 38 +− 3% of controls).
DISCUSSION
The accumulation of metabolites from the alternative oxidative
pathways of propionyl-CoA is the biochemical hallmark of PA.
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Figure 4 Chain-length-specific effects of acyl-CoA esters (A) and fatty acids
(B) on PDHc activity
(A) Acyl-CoA esters: spectrophotometric analysis of PDHc activity was performed in purified
enzyme from porcine heart using short-, medium- and long-chain monocarboxylic acyl-CoA
esters. The Figure summarizes the I50 values of acyl-CoA esters. Values are given as means.
Experiments were performed at least in triplicate. (B) Fatty acids: in contrast with acyl-CoA
esters, corresponding short- and medium-chain fatty acids (up to 1 mM) did not inhibit PDHc
activity in purified enzyme from porcine heart. PDHc activity was determined under standard
conditions. Values were normalized to 100 % (dotted line) and are given as the means +− S.D.
Experiments were performed at least in triplicate.
During metabolic crisis, additional biochemical abnormalities
such as lactic acidosis, hyperketosis and hypoglycaemia indicate
the development of severe mitochondrial dysfunction resulting
in impairment of energy metabolism [1]. The present study
significantly adds to the understanding of these mechanisms
demonstrating (i) a severe bioenergetic disturbance and ultra-
structural changes of mitochondria in muscle tissue of PA
patients and (ii) propionyl-CoA-induced synergistic inhibition
of PDHc, KGDHc and complex III in vitro. These results
support the hypothesis that secondary mitochondrial dysfunction
induced by accumulating toxic metabolites plays a major role in
the pathomechanisms of PA [7]. We clearly demonstrated that
propionyl-CoA, but not propionate, is the major toxic metabolite
involved in this scenario.
Figure 5 BN-PAGE of OXPHOS complexes in muscle homogenates
Proteins (40 µg) of solubilized muscle homogenates from patient 2 (P) and control (C) were
analysed by BN-PAGE (5–15 % gel) for the separation of multisubunit complexes. (A) In-gel
activity assay of mitochondrial complex I confirming a decrease in activities of patient 2 compared
with control samples. (B) A second gel was run in duplicate and Western-blot analysis was
performed using antibodies against complex I subunit 39 kDa, complex II subunit 70 kDa and
complex III subunit Core 2. (C) A second dimension was run and Western-blot analysis was
performed using antibodies against OXPHOS complexes I (ND6), III (Core 2) and IV [COX2
(cytochrome oxidase 2)] and cyclophilin B as a loading control. Arrows indicate the first and
second dimensions.
Figure 6 Ultrastructural changes in muscle tissue of PA patients
Electron microscopy of muscle biopsy specimens (musculus vastus lateralis dexter) of both PA
patients was performed. (A) Patient 1: muscle fibre with many lipid droplets (the large clear
globules). (B) Patient 1: mitochondrion with a crystalline inclusion. (C) Patient 2: large swollen
mitochondrion with disrupted cristae and two mitochondria with a dark globular inclusion.
PDHc is a bioenergetic bottleneck coupling cytosolic anaerobic
glycolysis with the mitochondrial tricarboxylic acid cycle and
OXPHOS. Not surprisingly, inherited PDHc deficiency results in a
severe disturbance of energy metabolism and frequently in a fatal
disease course [20]. In analogy, secondary inhibition of PDHc
by propionyl-CoA can be suggested as an important mechanism
inducing energy failure in PA, which is confirmed by severely
reduced ATP and phosphocreatine concentrations in muscle tissue
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of PA patients and increased serum lactate concentrations. In line
with this, multiple organ failure in PA patients predominantly
manifests in tissues with a high energy demand, such as the cen-
tral nervous system (encephalopathy, movement disorders and
developmental retardation), skeletal muscle (myopathy), heart
muscle (cardiomyopathy) and bone marrow (pancytopenia)
[1,3]. Apart from mammalian species, propionyl-CoA-induced
inhibition of PDHc has recently been suggested as a major
mechanism underlying the antibacterial and antifungal properties
of propionate [4]. Thus propionyl-CoA-induced mitochondrial
dysfunction can be regarded as a common final pathway involved
in different conditions, i.e. inherited disorders of propionate
metabolism and propionate toxicity. Future studies should focus
on concentration-dependent effects of propionyl-CoA in tissues of
children affected with PA. However, since the amount of a muscle
biopsy specimen in children is always very limited because of
ethical and functional considerations, this important aspect could
not be investigated additionally in the present study.
In addition to PDHc inhibition, alternative mechanisms for
propionyl-CoA and metabolites of alternative propionate oxid-
ation should be considered as relevant. In particular, inhibition
of respiratory chain complex III (the present study) and the
tricarboxylic acid cycle enzymes KGDHc (the present study),
citrate synthase [5] and succinyl-CoA synthetase [4] may
also contribute to impaired energy metabolism in this disease.
Interestingly, inherited deficiency of succinyl-CoA synthetase
caused by deleterious mutations in the SUCLA2 gene has recently
been associated with encephalomyopathy and mtDNA dep-
letion [21], linking the tricarboxylic acid cycle with mtDNA
homoeostasis [21,22]. In addition, increased oxidative stress,
which has been demonstrated in an in vitro model for disorders
of propionate metabolism, induces mtDNA damage [23,24].
Interestingly, the amount of mtDNA and the activities of OXPHOS
complexes I, III and IV, which are partially encoded by mtDNA,
were significantly decreased in muscle tissue of both PA patients;
however, it remains unclear whether this result reflects a causal
link. Besides mtDNA homoeostasis, other secondary or tertiary
targets might be involved but have not yet been identified.
PA shares a variety of biochemical and clinical similarities with
methylmalonic aciduria, which is caused by inherited deficiency
of methylmalonyl-CoA mutase or the synthesis or transport of its
cofactor, 5′-adenosylcobalamin [1]. We have recently hypothes-
ized that propionyl-CoA and metabolites deriving from propi-
onyl-CoA,suchas2-methylcitrate,mightactasendogenousneuro-
toxins also in this disease, whereas methylmalonate most likely
plays a minor role [13,14,25]. Since the manifestation of secon-
dary metabolic blocks is pathophysiologically relevant in PA and
methylmalonic aciduria, it is of interest to investigate whether
alternative energy substrates such as succinate and citrate might be
beneficial for metabolic maintenance treatment and intensified
emergency treatment of these patients helping to restore mitochon-
drial energy metabolism and to prevent multiple organ failure.
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